Record income and improved …

• Revenue: 4.2 million USD for the fourth quarter of 2024, including $ 2.7 million from ongoing sales and $ 1.5 million from the one-time sale of capital equipment.

• Sales growth: 108% increase compared to $ 2 million in the fourth quarter of 2023.

• Gross marge: 71% in the fourth quarter of 2024, compared to 52% in the fourth quarter of 2023.

• Operating costs: $ 11.3 million in the fourth quarter of 2024, compared to $ 9.8 million in the fourth quarter of 2023.

• Net lust: 4.9 million $ 0.20 per ordinary share in the fourth quarter of 2024, an improvement of 45% compared to a net loss of $ 8.9 million or $ 0.42 per ordinary share in the fourth quarter of 2023.

• Cash position: 54.9 million US dollars on December 31, 2024.

Appearance date: March 06, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• The profound medical corpe (NASDAQ: Prof) reported a record sales of $ 4.2 million for the fourth quarter of 2024 and marked an increase of 108% compared to the same period 2023.

• In the fourth quarter of 2024, the company achieved a gross parade of 71%, a significant improvement of 52% in the fourth quarter of 2023.

• The profound medical corpe (Nasdaq: Prof) reduced its net loss by 45% compared to the same quarter in the previous year.

• The company ended in 2024 with a strong cash position of 54.9 million dollars.

• With its randomized Captain study, the profound medical corpe (Nasdaq: Prof) is on the right track that has reached its registration target, which could improve its market position and reimbursement of reimbursement.

• In the fourth quarter of 2024, total operating costs rose to $ 11.3 million from USD 9.8 million in the fourth quarter of 2023, which indicates rising costs.

• Despite improvements, the company still recorded a net loss of $ 4.9 million for the fourth quarter of 2024.

• The company has not reached its goal of reaching 75 locations by the end of 2024.

• The profound medical corpe (Nasdaq: Prof) changes to a capital sales model, which can possibly be challenges in predictability and execution.

• There is uncertainty about the time and the extent of the payments of Medicare and private insurers who could affect the cash flow.

Q: Can you discuss the confidence of the projected strong growth rates for 2025 and beyond, especially in the context of the new Medicare refund environment? A: Arun Menawat, CEO, explained that the clinical value of your product is well received and that the economic models have profitability for hospitals due to higher reimbursement rates. The company had a strong fourth quarter in terms of capital turnover and the sales team is energized. Tom Tamberrino, CCO, added that the Medicare cover has increased inquiries and pursues private payers to ensure a more comprehensive coverage that supports its growth forecasts.